i

EPA REGISTRATION DIVISION COMPANY NOTICE OF FILING FOR 

PESTICIDE PETITIONS PUBLISHED IN THE FEDERAL REGISTER 

EPA Registration Division contact: Jennifer Urbanski (703) 347-0156

TEMPLATE:

E. I. DuPont de Nemours and Company, DuPont Crop Protection

3F8158

EPA has received a pesticide petition (3F8158) from E. I. DuPont de Nemours 

and Company, DuPont Crop Protection, Wilmington, Delaware requesting, pursuant to 

section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 

346a(d), to amend 40 CFR part 180

1. by establishing a tolerance for residues of

chlorantraniliprole, 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)-

carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide in or on the raw 

agricultural commodity peanuts at 0.06 ppm and peanut hay at 90 ppm. EPA has 

determined that the petition contains data or information regarding the elements set forth 

in section 408 (d)(2) of FDDCA; however, EPA has not fully evaluated the sufficiency 

of the submitted data at this time or whether the data supports granting of the petition. 

Additional data may be needed before EPA rules on the petition.

A. Residue Chemistry

1. Plant metabolism. The metabolism of chlorantraniliprole is adequately 

understood to support the proposed exemption from the requirement of 

tolerances. Studies in apple, lettuce, rice, tomato, and cotton when treated at 

proposed label rates showed no significant metabolites. The only significant 

residue is the parent compound.

Livestock Metabolism. The metabolism of chlorantraniliprole in ruminants and 

poultry is adequately understood to support the exemption from the 

requirement of tolerances. Lactating goat and laying hen metabolism studies 

were conducted. The goat and hen rapidly excreted >93% and >98% of the 

dosed radiolabeled residues, respectively. 

The metabolic pathway in poultry and ruminant (goat) animals was consistent. 

There is no reasonable expectation of transfer of finite residues of 
2

chlorantraniliprole and its metabolites to fat, meat, milk, and eggs.

2. Analytical method. Since chlorantraniliprole and its metabolic degradates are 

not of toxicological concern, analytical methods are not applicable. 

3. Magnitude of residues. Field residue trials were conducted with 

chlorantraniliprole on the raw agricultural commodity peanuts. Six MOR trials 

were conducted. The locations of the field trials were selected to represent the 

regions with most peanut production. A foliar broadcast spray of 

chlorantraniliprole was applied at the rate of 0.1 lb ai/A/application. The peanut 

treated plots received two applications targeted at 1 day before harvest (1-day 

PHI) of mature crop. Concurrent recoveries from control samples fortified at 

0.010 to 0.1 mg/kg of chlorantraniliprole ranged from 98 to 100%. Residue levels 

in peanuts averaged 0.01 ppm and ranged from not detected to 0.046 ppm.

Numerous residue studies have been conducted on many crops in the United 

States and globally by the registrant and by other organizations such as the IR-4 

Project. The relevant U.S. and foreign residue study reports required to support 

use of chlorantraniliprole and existing tolerances in the United States have been 

submitted to EPA and reviewed as part of prior registration actions for this active 

ingredient.

B. Toxicological Profile

1. Acute toxicity. Based on EPA criteria, chlorantraniliprole is classified as 

follows for Toxicity Categories:

Guideline Title Results Category

870.1100

870.1200

870.1300

870.2400

870.2500

870.2600

Acute Oral Toxicity

Acute Dermal Toxicity

Acute Inhalation Toxicity

Primary Eye Irritation

Primary Dermal Irritation

Skin Sensitization

LD50: >5,000 mg/kg (Rat)

LD50: >5,000 mg/kg (Rat)

LC50: >5.1 mg/L (Rat)

Mild irritation (Rabbit)

No irritation (Rabbit)

Not a sensitizer (Mouse LLNA)

Category IV

Category IV

Category IV

Category IV

Category IV

---------------

Formulated products are as equally non-toxic following acute exposures as is 

technical chlorantraniliprole. The acute inhalation toxicity for the suspension 

concentrate formulation could not be determined above the maximum 

practically attainable atmospheric aerosol concentration of 2 mg/L. 

There was no evidence of neurotoxicity in rats following a single limit dose of 

2,000 mg/kg
3

2. Genotoxicty. Chlorantraniliprole has shown no genotoxic activity in the 

following listed in vitro and in vivo tests: 

 Bacterial reverse mutation 

 In vitro mammalian gene mutation (CHO/HGPRT) 

 In vitro chromosomal aberration (human lymphocytes) 

 In vivo mouse micronucleus

3. Reproductive and developmental toxicity. In developmental toxicity studies in 

rats and rabbits, chlorantraniliprole exhibited no effects on any parameter in 

pregnant females or their offspring at levels up to and including the maximum 

tested dose of 1,000 mg/kg bw/day. 

No reproductive toxicity was observed in a two-generation reproduction study 

with chlorantraniliprole in rats. No adverse effects were observed on 

reproduction, fertility, sperm parameters, estrous cycle, litter size, pup survival 

and developmental landmarks up to the maximum tested dose of 20,000 ppm in 

the diet. There were no adverse histological findings indicative of reproductive 

toxicity. There was a slight reduction in the F1 pup (but not F2 pup) weight 

during lactation at the highest dose level (mean maternal intake during lactation 

equal to 3,118 mg/kg bw/day); this was attributed, in part, to weight loss in one 

dehydrated dam during lactation which had a litter with some of the lowest pup 

weights. The slight change in pup weight was without subsequent effects since 

overall body weight, weight gain and development in F1 rats fed 20,000 ppm 

were similar to control animals. 

4. Subchronic toxicity. Subchronic (90 day) feeding studies were conducted 

with rats, mice and dogs. No adverse effects were observed at the highest dietary 

concentrations tested of 20,000 ppm in rats (1,188 mg/kg bw/day for males and 

1,526 mg/kg bw/day for females), 7,000 ppm in mice (1,135 mg/kg bw/day for 

males and 1,539 mg/kg bw/day for females) and 40,000 ppm in dogs (1,163 

mg/kg bw/day for males and 1,220 mg/kg bw/day for females). 

Chlorantraniloprole showed no evidence of immunotoxicity in 28-day feeding 

studies in rats or mice and no evidence of neurotoxicity in a 90-day feeding study 

in rats at dietary concentrations greater than the limit dose of 1,000 mg/kg 

bw/day.

A 28-day dermal toxicity study in rats was conducted at doses of 100, 300 and 

1,000 mg/kg bw/day. The NOAEL for male and female rats was 300 mg/kg 

bw/day based on reductions in body weight gain and food efficiency at 1,000 

mg/kg bw/day.

No adverse target organ effects were observed in any subchronic toxicity study.

5. Chronic toxicity. Chlorantraniliprole was not carcinogenic in either a 2-year 

study in rats or an 18-month study in mice. The NOAEL for chronic toxicity in 

the 18-month mouse study was 1,200 ppm (158 mg/kg bw/day in males) and was 
4

based on eosinophilic foci accompanied by hepatocellular hypertrophy and 

increased liver weight. 

In rats, there were no adverse effects on any in-life parameter in either males or 

females administered chlorantraniliprole up to and including a maximum dietary 

concentration of 20,000 ppm for 2 years (805 and 1,076 mg/kg bw/day, 

respectively). 

In a one-year feeding study in dogs, the NOAEL was the highest dose tested, 

40,000 ppm (1,164 and 1,233 mg/kg/day in males and females, respectively).

6. Animal (Rat) metabolism. The absorption of [14C]-chlorantraniliprole in rats 

was rapid with peak concentrations occurring at 5-12 hours after single dose 

administration. Tissue distribution of the absorbed dose was extensive and 

indicated low potential for accumulation. Excretion was substantially complete 

by 48-72 hours after dosing (>90%). 

Following 14 days of oral administration 14C residues were readily eliminated 

from the plasma and tissues and confirmed minimal potential for accumulation. 

The profile of metabolites in urine and feces indicated extensive metabolism 

consistent with that observed for the single dose study.

7. Metabolite toxicology. Due to the extremely low toxicity of the parent 

compound and the extensive metabolism observed in mammalian systems, 

chlorantraniliprole metabolites are not expected to result in any significant 

toxicity. Toxicology studies conducted with metabolites support this conclusion

8. Endocrine disruption. No adverse effects were observed on any endocrine 

tissue in short- and long-term studies in rats, mice and dogs.

C. Aggregate Exposure

1. Dietary exposure. [Insert text.]

i. Food. Because an endpoint attributable to a single dose was not identified, the 

dietary exposure assessment considered only chronic exposure. 

Chronic dietary exposure assessments were conducted using the Dietary Exposure 

Evaluation Model (DEEM-FCIDTM, Version 2.03) which uses food consumption 

data from the U.S. Department of Agriculture’s Continuing Surveys of Food 

Intakes by Individuals (CSFII) from 1994-1996 and 1998. The chronic dietary 

exposure assessment was conducted using a chronic reference dose of 1.58 mg/kg 

bw/day based on the NOAEL established in the 18-month study in mice. DuPont 

has conducted chronic assessments which assume that 100% of all crops –

including those not labeled - are treated with chlorantraniliprole and that all crops 

contain residues at tolerance level or at residue levels equal to tolerance levels for 

similar crops. In particular all leafy vegetables, including leaves of root and tuber 

vegetables and leafy vegetables including brassica vegetables, are assumed to 
5

have residues of 15 parts per million. All other human foods (including plant and 

animal commodities) are assumed to have residues of 2 parts per million.

These assumptions result in conservative, health-protective estimates of exposure 

which are well below the Agency’s level of concern (100% of the cPAD). The 

maximum estimate is less than 11% of the cPAD for all population subgroups. 

ii. Drinking water. A drinking water assessment for chlorantraniliprole, conducted 

based on PRZM/EXAMS (Pesticide Root Zone Model/Exposure Analysis 

Modeling System), was used to calculate the surface water estimated drinking 

water concentrations (EDWCs) and the Screening Concentration in Ground Water 

(SCI-GROW) model was used to calculate the groundwater EDWC. The EDWCs 

do not exceed the Agency’s level of concern.

2. Non-dietary exposure. Residential exposure (non-occupational, non-dietary 

exposure to consumers) was conservatively assessed for dermal post-application 

exposure (children and adults), and for children the oral exposures via hand-tomouth, object-to-mouth, and incidental ingestion of soil were also assessed. The 

margins of exposure (MOE) greatly exceed the 100-fold MOE required for these 

routes and from the combined children’s incidental oral ingestion. Therefore, 

residential non-dietary exposure is not a concern.

D. Cumulative Effects

It is not necessary at this time to consider cumulative effects because there is no 

indication that toxic effects of chlorantraniliprole have a common mechanism 

with those of any other chemical compounds. 

E. Safety Determination

1. U.S. population. Based on risk assessments performed using worst-case 

exposure assumptions there is a reasonable certainty that no harm will result to 

the general population from the aggregate exposure to chlorantraniliprole. No 

additional safety factors are warranted.

2. Infants and children. Based on the risk assessments performed using worst-case 

exposure assumptions there is a reasonable certainty that no harm will result to 

the infants and children from the aggregate exposure to chlorantraniliprole. No 

additional safety factors are warranted.

F. International Tolerances

Numerous chlorantraniliprole MRLs have been established or are expected to be 

established supporting registrations in 82 countries. Codex MRLs have also been 

established for chlorantraniliprole on numerous crops.